Manidipine (89226-75-5) is a clinically useful antihypertensive.1,2 It is an inhibitor of L- and T-type calcium channels with high selectivity for vasculature.? Manidipine has recently been found to be an inhibitor (IC50 = 4.8 μM) of the SARS-CoV-2 main protease, 3CLpro.3 It also acts as an early entry inhibitor of human cytomegalovirus (EC50 = 3.57 μM) via inhibition of the Immediate-Early 2 (IE2) protein.4
Kakihana et al. (1988), Antihypertensive effect of CV-4093·2HCl, a new calcium antagonist, in three rat models of hypertension; Jpn. J. Pharmacol., 48 223
McKeage (2004), Manidipine: a review of its use in the management of hypertension; Drugs, 64 1923
Ghahremanpour et al. (2020), Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2; ACS Med. Chem. Lett., 11 2526
Mercorelli et al. (2018), Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early entry inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein; Antiviral Res., 150 130
